KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Clover Health Investments (CLOV) EBITDA (2019 - 2025)

Clover Health Investments' EBITDA history spans 7 years, with the latest figure at -$49.3 million for Q4 2025.

  • For Q4 2025, EBITDA fell 100.84% year-over-year to -$49.3 million; the TTM value through Dec 2025 reached -$83.4 million, down 97.61%, while the annual FY2025 figure was -$83.4 million, 97.61% down from the prior year.
  • EBITDA reached -$49.3 million in Q4 2025 per CLOV's latest filing, down from -$24.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $7.7 million in Q2 2024 to a low of -$317.5 million in Q2 2021.
  • Average EBITDA over 5 years is -$63.4 million, with a median of -$44.4 million recorded in 2021.
  • Peak YoY movement for EBITDA: plummeted 6439.41% in 2021, then surged 127.05% in 2024.
  • A 5-year view of EBITDA shows it stood at -$188.5 million in 2021, then surged by 56.06% to -$82.8 million in 2022, then grew by 18.19% to -$67.8 million in 2023, then skyrocketed by 63.81% to -$24.5 million in 2024, then tumbled by 100.84% to -$49.3 million in 2025.
  • Per Business Quant, the three most recent readings for CLOV's EBITDA are -$49.3 million (Q4 2025), -$24.1 million (Q3 2025), and -$10.3 million (Q2 2025).